Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alkermes reports robust Q4 earnings, eyes growth through innovative products

Alkermes demonstrated strong financial performance in Q4 2022, driven by the successful launch of LYBALVI and continued growth in key products.
The company's focus on expanding market access, enhancing product awareness, and strategic investments position it for future success and revenue growth.
Challenges in meeting revenue targets, managing profitability, and refining market strategies require careful navigation and proactive decision-making.
Opportunities in advancing product launches, expanding the pipeline, and leveraging scientific advancements offer avenues for sustained growth and market leadership.

Alkermes reports robust Q1 earnings, eyes global expansion and innovation

Alkermes delivered strong financial results in Q1 2023, driven by key proprietary products and strategic initiatives like the LYBALVI direct-to-consumer campaign.
While facing challenges such as commercial pressures and financial optimization queries, the company remains focused on growth and profitability.
Opportunities for international expansion, strategic investments, and innovative drug development position Alkermes for future success and value creation for shareholders.

Alkermes reports strong Q2 earnings, eyes growth through strategic initiatives

Alkermes' Q2 2023 Earnings Call reflects robust financial performance, strategic focus on key products, and ongoing investment in growth opportunities. Resolving arbitration, strong net income, and cash position underscore financial strength amidst operational challenges.

Alkermes posts solid Q3 results, plans neuroscience focus post-separation

Alkermes delivered strong Q3 results with revenue growth across key products and a focus on disciplined cost management post-separation.
The company showcased promising data for ALKS 2680 and outlined strategic priorities to drive future growth in the neuroscience sector.
While challenges like managing expenses and addressing safety concerns exist, opportunities in expanding product offerings and market access strategies are key for future success.
Investors should monitor Alkermes' progress in optimizing dosing profiles, mitigating adverse events, and achieving profitability targets amidst competitive pressures.

Alkermes reports stellar 2023 results, eyes transformative neuroscience advancements

Alkermes' strong financial performance in 2023 sets the stage for continued growth and innovation in 2024.
Key products like LYBALVI, ARISTADA, and VIVITROL demonstrated robust sales growth, underpinning the company's success.
Addressing challenges such as liver toxicity and visual disturbances will be crucial for sustaining growth and product development.
Opportunities in advancing neuroscience studies and capital allocation strategies position Alkermes for future success and value creation.

Alkermes reports strong Q1 earnings, eyes growth through product differentiation

Alkermes' Q1 performance reflects solid revenue growth and profitability, driven by key product successes.
While facing challenges such as expense management and market access, the company remains well-positioned.
Opportunities for growth lie in expanding prescriber base, accelerating revenue, and leveraging product strengths.
Overall, Alkermes demonstrates financial resilience and strategic focus on sustainable growth.

Alkermes (ALKS) reports robust Q2 earnings, focuses on growth strategies

Alkermes (ALKS) delivered strong revenue performance in Q2 2024, driven by proprietary product growth and effective expense management.
The company showcased resilience amidst revenue challenges and emphasized strategic initiatives for profitability and pipeline advancement.
While facing industry challenges, Alkermes remains poised for growth through innovation, market expansion, and operational efficiency.
Strategic focus on advancing key products, exploring growth opportunities, and prudent financial management underpin Alkermes' growth trajectory.

Alkermes excels in Q3 earnings, targets $200M EBITDA in 2025

Alkermes demonstrated strong sales performance in Q3 2024, with a strategic focus on profitability and cash flow for the future. While facing challenges in certain revenue streams, the company is poised to capitalize on growth opportunities and drive financial success in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes (ALKS) delivered earnings and revenue surprises of 2700.00% and 11.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Tops Q3 Earnings and Revenue Estimates

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year 2020. "Over the past several months, we achieved a number of important milestones in our development...

Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss the company's third quarter 2020 financial results. Management will also provide an update on the...

Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Neurocrine Biosciences

ACADIA Pharma

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Ionis Pharma

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied.

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.

Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote

An FDA joint committee's favorable votes on an Alkermes drug candidate to treat bipolar I and schizophrenia came just weeks ahead of an expected key FDA decision and sent ALKS stock rising. The post Alkermes Nears FDA Ruling For Its Bipolar Treatment With Key Endorsement; ALKS Stock Jumps appeared first on Investor's Business Daily.

Alkermes Nears FDA Ruling For Its Bipolar Treatment With Key Endorsement; ALKS Stock Jumps

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug...

FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee,...

Trading in Alkermes Ordinary Shares Halted Today

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2020 joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and...

Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831

Ligand Pharmaceuticals

LGND vs. ALKS: Which Stock Is the Better Value Option?

LGND or ALKS: Which Is the Better Value Stock Right Now?

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, ALKS 4230, administered intravenously as monotherapy...

Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept.

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the European Society for Medical Oncology (ESMO) Virtual Congress,.

Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Why Is Alkermes (ALKS) Down 12% Since Last Earnings Report?

Anika Therapeutics

ANIK vs. ALKS: Which Stock Is the Better Value Option?

ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S.

Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020

Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.

Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors

DUBLIN, Aug. 19, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of a variety of advanced, malignant solid tumors.

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

ANIK or ALKS: Which Is the Better Value Stock Right Now?

Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.

Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates

Alkermes plc (ALKS) CEO Richard Pops on Q2 2020 Results - Earnings Call Transcript

Alkermes (ALKS) delivered earnings and revenue surprises of 700.00% and 3.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates

DUBLIN, July 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2020 and provided updated financial expectations for full-year 2020. The company had previously withdrawn its 2020 financial expectations due to uncertainties.

Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations

Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Alkermes Stock (ALKS)